Last reviewed · How we verify
A Randomized, Open-label Clinical Trial to Assess the Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Details
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
|---|---|
| Phase | Phase 1 |
| Status | RECRUITING |
| Enrolment | 32 |
| Start date | 2025-09-22 |
| Completion | 2029-10 |
Conditions
- Cervical Cancer
Interventions
- PVX7
Primary outcomes
- Safety of PVX7 as assessed by adverse events — 12 months
To assess the safety of PVX7 immunotherapy to patients with advanced cervical cancer who have completed primary therapy by evaluating Adverse Events (AEs). - Feasibility of PVX7 — 12 months
To assess the feasibility of PVX7 immunotherapy to patients with advanced cervical cancer who have completed primary therapy. Feasibility is measured by the ability of patients to receive all three doses of vaccine.
Countries
United States